Barclays Starts Spring Works Therapeutics (SWTX) at Overweight
Barclays analyst Peter Lawson initiates coverage on Spring Works Therapeutics (NASDAQ: SWTX) with a Overweight rating and a price target of $48.00.
Shares of Spring Works Therapeutics closed at $30.21 yesterday.
You May Also Be Interested In
- UPDATE: Oppenheimer Starts Golub Capital BDC (GBDC) at Outperform
- Citi Starts Knorr-Bremse AG (KBX:GR) at Neutral
- UPDATE: China Renaissance Starts FinVolution (FINV) at Buy
Create E-mail Alert Related CategoriesNew Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!